

Cipla inks agreement with IICT to develop COVID-19 drug

20 March 2020 | News

IICT will be working of existing anti-viral drugs like remdesivir, favipiravir and bolaxavir



Mumbai based pharmaceutical company Cipla has teamed up with the Hyderabad based Council of Scientific & Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT) to develop potential candidates for treating COVID-19.

Scientists from IICT will be working of existing anti-viral drugs like remdesivir, favipiravir and bolaxavir.

Further on, Cipla will start the next phase of trials, take up regulatory authority approvals and subsequent mass production of the anti-viral drugs, for the treatment of COVID-19.